Exarmed Pharma Private Limited - Due diligence report

A 360° intelligence report on Exarmed Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2019-01-08 Gujvail, Telangana Converted To Llp Unlisted Active Compliant
Share
EP Exarmed Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Exarmed Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
60/100
Trust Score
Moderate

Exarmed Pharma Private Limited is assessed as Moderate with a Trust Score of 60/100. Exarmed Pharma Private Limited is a private limited indian non-government company incorporated in 2019, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.

Report generated on 23 Jul 2026 from the latest processed filings. Exarmed Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
60/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
45/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 30/100 Caution Indicated
  • Company status is "Converted To Llp" - not Active.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
BALA MURALI KRISHNA THIPPABHOTLA 01234567 Director 01/04/2018 6 yrs Approved
JAHNAVI PUCHAKAYALA 01234567 Director 01/04/2018 6 yrs Approved
VAJRALA BHULAKSHMI 01234567 Director 01/04/2018 6 yrs Approved
MADHUSUDHAN REDDY 01234567 Director 01/04/2018 6 yrs Approved
Ganamoor Madhusudhan Reddy 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • MADHUSUDHAN REDDY has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
5 allotment(s) · 0 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
Apogen Remedies Private Limited Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 45
Growth signals & trust indicators
Revenue acceleration: +2.1x over 3 year(s).
Latest year revenue grew 24%.
Operating for 7 years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
Statutory filings appear overdue.
Adverse company status: Converted To Llp.
Compliance score is weak (30/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence44/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 14 events
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
01 Nov 2022
Director appointed
MADHUSUDHAN REDDY (Company Secretary)
Director appointed
Ganamoor Madhusudhan Reddy (Company Secretary)
08 Sep 2021
Securities allotted
5000000 Equity Shares - 5.00 cr raised
31 Dec 2020
Director ceased
BALA MURALI KRISHNA THIPPABHOTLA
21 Jul 2020
Securities allotted
2500000 Equity Shares - 2.50 cr raised
25 Nov 2019
Securities allotted
1050000 Equity Shares - 1.05 cr raised
26 Aug 2019
Securities allotted
2690000 Equity Shares - 2.69 cr raised
12 Jul 2019
Securities allotted
2250000 Equity Shares - 2.25 cr raised
01 Jul 2019
Director appointed
BALA MURALI KRISHNA THIPPABHOTLA (Director)
08 Jan 2019
Incorporated
Registered with Roc Hyderabad
Director appointed
JAHNAVI PUCHAKAYALA (Director)
Director appointed
VAJRALA BHULAKSHMI (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 3 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
5 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Divtatv Wellness Private Limited U24290DL2020PTC368699 Delhi, Delhi, India
Felicis Agros Private Limited U01100MP2021PTC054445 Indore, Madhya Pradesh, India
Bvk'S Bioscience Private Limited U24100GJ2015PTC083300 Kalol, Gujarat, India
Amikeva Private Limited U24290MH2021PTC363823 Mumbai, Maharashtra, India
Damoh Wellness Private Limited U93000MH2022PTC375533 Mumbai, Maharashtra, India
Garnichem Pharma Private Limited U74999MH2017PTC293472 Vasai, Maharashtra, India
Grh Health Private Limited U74999GJ2018PTC104487 Daskroi, Gujarat, India
Maklin Orgamics Private Limited U24290KA2017PTC106928 Ballari, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Exarmed Pharma Private Limited before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Exarmed Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Exarmed Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Exarmed Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Exarmed Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Exarmed Pharma Private Limited an active company?

Exarmed Pharma Private Limited has MCA status “Converted To Llp” with a compliance score of 30/100 (Caution Indicated).

Is Exarmed Pharma Private Limited financially healthy?

Exarmed Pharma Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Exarmed Pharma Private Limited?

Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Exarmed Pharma Private Limited?

Promoters hold a majority stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Exarmed Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Exarmed Pharma Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 30/100 (Caution Indicated).

Is it risky to lend to Exarmed Pharma Private Limited?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.